FibroBiologics Files 2024 Proxy Statement
Ticker: FBLG · Form: DEF 14A · Filed: Apr 23, 2025 · CIK: 1958777
Sentiment: neutral
Topics: proxy-statement, governance, board-of-directors
TL;DR
FibroBiologics DEF 14A out, board members Pete O'Heeron, Hamid Khoja, Ruben Garcia listed. Vote wisely!
AI Summary
FibroBiologics, Inc. filed its definitive proxy statement (DEF 14A) on April 23, 2025, for the fiscal year ending December 31, 2024. The filing details information related to the company's governance and shareholder matters. Key individuals mentioned in relation to board membership include Pete O'Heeron, Hamid Khoja, and Ruben A. Garcia, each noted as a member as of December 27, 2024.
Why It Matters
This filing provides shareholders with crucial information regarding company leadership, voting matters, and executive compensation, enabling informed participation in corporate governance decisions.
Risk Assessment
Risk Level: low — This is a routine DEF 14A filing providing information to shareholders and does not inherently present new financial risks.
Key Numbers
- 20241231 — Fiscal Year End (The period covered by the proxy statement.)
- 20250423 — Filing Date (The date the definitive proxy statement was filed with the SEC.)
Key Players & Entities
- FibroBiologics, Inc. (company) — Registrant
- Pete O'Heeron (person) — Board Member
- Hamid Khoja (person) — Board Member
- Ruben A. Garcia (person) — Board Member
FAQ
What is the primary purpose of a DEF 14A filing?
A DEF 14A filing, or definitive proxy statement, is used by companies to solicit shareholder votes on important corporate matters, such as the election of directors, executive compensation, and other proposals.
Who are the listed board members as of December 27, 2024?
As of December 27, 2024, the listed board members are Pete O'Heeron, Hamid Khoja, and Ruben A. Garcia.
What is the company's standard industrial classification?
FibroBiologics, Inc. is classified under 'PHARMACEUTICAL PREPARATIONS [2834]'.
When was FibroBiologics, Inc. incorporated?
FibroBiologics, Inc. was incorporated in Delaware (DE).
What is the business address of FibroBiologics, Inc.?
The business address is 455 E. MEDICAL CENTER BLVD, SUITE 300, HOUSTON, TX 77598.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 23, 2025 by Pete O'Heeron regarding FibroBiologics, Inc. (FBLG).